Literature DB >> 11959541

Antiparasitic agent atovaquone.

Aaron L Baggish1, David R Hill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11959541      PMCID： PMC127192          DOI： 10.1128/AAC.46.5.1163-1173.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  135 in total

1.  Malarone-donation programme in Africa.

Authors:  P B Bloland; P N Kazembe; W M Watkins; O K Doumbo; O C Nwanyanwu; T K Ruebush
Journal:  Lancet       Date:  1997-11-29       Impact factor: 79.321

2.  Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team.

Authors:  B Høgh; P D Clarke; D Camus; H D Nothdurft; D Overbosch; M Günther; I Joubert; K C Kain; D Shaw; N S Roskell; J D Chulay
Journal:  Lancet       Date:  2000-12-02       Impact factor: 79.321

Review 3.  Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.

Authors:  S Looareesuwan; J D Chulay; C J Canfield; D B Hutchinson
Journal:  Am J Trop Med Hyg       Date:  1999-04       Impact factor: 2.345

4.  Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite.

Authors:  I K Srivastava; H Rottenberg; A B Vaidya
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

5.  Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.

Authors:  M Opravil; B Hirschel; A Lazzarin; A Heald; M Pechère; S Rüttimann; A Iten; J von Overbeck; D Oertle; G Praz
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

6.  Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa.

Authors:  R Steffen; E Fuchs; J Schildknecht; U Naef; M Funk; P Schlagenhauf; P Phillips-Howard; C Nevill; D Stürchler
Journal:  Lancet       Date:  1993-05-22       Impact factor: 79.321

7.  Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.

Authors:  C Katlama; S De Wit; E O'Doherty; M Van Glabeke; N Clumeck
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

8.  Examination of some factors responsible for a food-induced increase in absorption of atovaquone.

Authors:  P E Rolan; A J Mercer; B C Weatherley; T Holdich; H Meire; R W Peck; G Ridout; J Posner
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

9.  Atovaquone and proguanil for Plasmodium falciparum malaria.

Authors:  P D Radloff; J Philipps; M Nkeyi; D Hutchinson; P G Kremsner
Journal:  Lancet       Date:  1996-06-01       Impact factor: 79.321

10.  A mechanism for the synergistic antimalarial action of atovaquone and proguanil.

Authors:  I K Srivastava; A B Vaidya
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191
View more
  52 in total

Review 1.  Classical and alternative components of the mitochondrial respiratory chain in pathogenic fungi as potential therapeutic targets.

Authors:  Vicente de Paulo Martins; Taisa Magnani Dinamarco; Carlos Curti; Sérgio Akira Uyemura
Journal:  J Bioenerg Biomembr       Date:  2011-02       Impact factor: 2.945

2.  Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis.

Authors:  Wai Kit Chew; Ignacio Segarra; Stephen Ambu; Joon Wah Mak
Journal:  Antimicrob Agents Chemother       Date:  2012-01-23       Impact factor: 5.191

Review 3.  Unravelling Toxoplasma treatment: conventional drugs toward nanomedicine.

Authors:  Sanaz Jafarpour Azami; Hanieh Mohammad Rahimi; Hamed Mirjalali; Mohammad Reza Zali
Journal:  World J Microbiol Biotechnol       Date:  2021-02-10       Impact factor: 3.312

4.  In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii.

Authors:  Lara Liv Bajohr; Ling Ma; Christian Platte; Oliver Liesenfeld; Lutz F Tietze; Uwe Gross; Wolfgang Bohne
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

Review 5.  Current therapies and future possibilities for drug development against liver-stage malaria.

Authors:  Rene Raphemot; Dora Posfai; Emily R Derbyshire
Journal:  J Clin Invest       Date:  2016-06-01       Impact factor: 14.808

6.  Atovaquone Inhibits Arbovirus Replication through the Depletion of Intracellular Nucleotides.

Authors:  Angelica Cifuentes Kottkamp; Elfie De Jesus; Rebecca Grande; Julia A Brown; Adam R Jacobs; Jean K Lim; Kenneth A Stapleford
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

7.  Combining Inhibitor Resistance-conferring Mutations in Cytochrome b Creates Conditional Synthetic Lethality in Saccharomyces cerevisiae.

Authors:  Martina G Ding; Jean-Paul di Rago; Bernard L Trumpower
Journal:  J Biol Chem       Date:  2009-01-29       Impact factor: 5.157

Review 8.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  1,4-naphthoquinone cations as antiplasmodial agents: hydroxy-, acyloxy-, and alkoxy-substituted analogues.

Authors:  Xiao Lu; Ali Altharawi; Jiri Gut; Philip J Rosenthal; Timothy E Long
Journal:  ACS Med Chem Lett       Date:  2012-10-01       Impact factor: 4.345

10.  Type II NADH dehydrogenase inhibitor 1-hydroxy-2-dodecyl-4(1H)quinolone leads to collapse of mitochondrial inner-membrane potential and ATP depletion in Toxoplasma gondii.

Authors:  San San Lin; Uwe Gross; Wolfgang Bohne
Journal:  Eukaryot Cell       Date:  2009-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.